Key Highlights

● Net sales fell and a reported loss per share was posted

● Core Earnings outlook was lowered

● All In outlook now excludes the infant formula Business to be divested

● Measured retailer inventory and soft European Demand were cited

Perrigo Company plc (NYSE:PRGO), a consumer self-care group covered here among value stocks, gave investors a full-year update that needs careful reading. The Dublin-based company reported lower third-quarter net sales, a reported loss per diluted share against a small profit in the prior-year period, and a lower adjusted operating margin. It also rewrote its outlook in a way that sends the main headline earnings ranges in opposite directions.

The range that measures the go-forward business, which the company labels Core, moved down. Core adjusted Diluted Earnings per Share are now expected in a lower band than the company offered previously, and the expected Core net sales range moved lower at both ends, pointing to a decline for the year. Core adjusted gross margin and adjusted Operating Margin expectations also came down.

The All In range, which covers the wider reported business, moved up on its face. That shift does not signal stronger trading. Beginning with fourth-quarter and full-year reporting, the Infant Formula business will be treated as discontinued operations, so the All In outlook now excludes it while still including other divested businesses. Taking out a business that had been running with planned under-absorption of factory costs lifts the margin and per-share figures that remain.

Read together, the Core line is the cleaner guide to how management views underlying demand, and that view has become more cautious. The company attributed the changes to the Infant Formula divestiture, more measured retailer inventory positioning ahead of the cough and cold season, and continued softness in the European consumer environment.

What the Quarter Delivered

On an All In basis, reported net sales fell from the prior-year quarter, while organic net sales fell by a smaller margin. Reported gross margin and adjusted gross margin both narrowed, and reported and adjusted operating margins contracted as well. Adjusted diluted earnings per share came in below the prior-year period, and the company noted that this measure absorbed an unfavorable effect from planned under-absorption in Infant Formula.

The Core business, which excludes Infant Formula and previously announced divestitures, showed a milder decline. Net sales slipped from the prior-year quarter, with both pricing and Volume and mix contributing to a modest organic decrease. Adjusted gross margin narrowed because of lower volumes and unfavorable mix, an effect partly cushioned by a net recovery of previously paid tariffs and by Market Share gains.

Core adjusted operating margin also narrowed. The company cited Gross Profit flow-through along with higher advertising, promotion and variable compensation, partly offset by benefits from its Operational Enhancement Program. Core adjusted earnings per share declined, and that result included a helpful contribution from a lower effective tax rate.

The tax line is worth noting. The adjusted effective tax rate fell in the quarter, reflecting changes in jurisdictional mix, and the company lowered its full-year adjusted tax rate assumption as well. Part of the per-share result therefore came from below the operating line rather than from the underlying trading performance. On the earnings call, management flagged tax-rate normalization and the end of one-time Tariff benefits as headwinds for next year.

Inside the Segments at Perrigo

Self Care, the largest segment, recorded lower net sales and a sharper decline in adjusted operating income. The company tied the sales decline to lower consumption, which led to more measured retailer inventory in Upper Respiratory and in Pain and Sleep, along with lower contract Manufacturing and unfavorable pricing. Healthy Lifestyle, which includes nicotine replacement, and Digestive Health, which includes laxatives, both grew. Profit fell because of production variances, mix and higher Advertising spend.

Specialty Care also reported lower sales and lower adjusted operating income. Women's Health grew strongly, led by ellaOne and Opill, but Skin Health weighed on the segment through lower store Brand and contract manufactured Minoxidil and lower Mederma sales. Production variances, Skin Health mix and higher Marketing reduced profit.

Infant Formula sales declined from the prior-year quarter, and the segment moved from an adjusted operating profit to a small adjusted operating loss. Store brand growth was more than offset by lower contract manufacturing volumes, which the company linked to a shift of certain shipments recorded in the second quarter. Planned under-absorption pressured profit, partly offset by lower operating expenses.

The All Other grouping stood out as the one area with higher adjusted operating income, even though its sales fell, mainly because of divestitures. The profit gain came from a net tariff recovery, productivity gains and lower Oral Care operating expenses.

Cautious Shelves Before Cough and Cold Season

The most discussed theme on the Earnings Call was retailer behavior. Interim President and Chief Executive Officer Albert Manzone said "retailers have taken a more measured approach to inventory" and indicated that the season appears to be shifting later in the calendar. Chief Financial Officer Eduardo Bezerra said the self-care decline was concentrated in upper respiratory and in pain and sleep.

An analyst from Hedgeye asked whether retailers were actively cutting stock or simply not rebuilding it. According to the transcript, Manzone responded that retailers did not load inventory for the season as they had in the past. He added that replenishment would follow if the season picks up, although the timing across the fourth quarter and the first quarter of next year remains unclear.

That framing leaves open the possibility that some sales are delayed rather than lost, but management did not commit to that outcome, and the revised outlook does not assume it in any stated way. Replenishment was described as dependent on how the season develops. The issue is relevant to the company because its store brand over-the-counter products depend on retailer ordering patterns as well as on what shoppers ultimately purchase.

Manzone also said US category volume "returned to modest growth" in the quarter, and that the company gained share in US store brand over-the-counter products on higher volume. He said E-commerce represents a meaningful portion of US volume and described it as a source of further improvement. Service levels to key retailers were described as high, which he said has supported co-innovation and demand generation work with those customers.

Europe Remains the Softer Half of the Story

Europe was the second Factor behind the outlook change. Bezerra said "the consumer environment remains challenging" and that it is tracking below prior expectations, leading management to take a more measured view for the remainder of the year. Manzone said European consumer trends remain soft but are improving sequentially.

The company nonetheless reported market share gains there. Manzone said value sales in key European brands grew in the quarter and that share increased across primary categories. He also used the phrase "leaky bucket" to describe some European brands and said he plans to support brands with potential. Those comments suggest that management sees uneven performance across the portfolio, rather than a uniform decline, in the region.

The Core sales decline did narrow as the year progressed, with management showing a smaller year-over-year drop in the third quarter than in either of the earlier quarters of the year. Core adjusted operating margin rose sequentially across the same quarters, which Manzone cited as evidence that "operations are becoming more consistent."

The Formula Deal and Its Accounting Echo

The sale announced in late October frames much of the outlook revision. Perrigo agreed to divest its infant formula Assets to MeridianMade, a US contract manufacturer, in a transaction combining an upfront cash payment at closing with a larger contingent amount tied to net sales milestones through the end of the decade. The combined potential consideration is modest relative to the sales the business generated over the previous year, according to figures reported by market data.

Closing is expected in the first half of next year, subject to customary conditions and regulatory approvals. Until then, the companies operate independently, and Perrigo keeps ownership and operational responsibility, according to market data. Perrigo expects a substantial non-cash Impairment loss in the fourth quarter from measuring the business as held for sale.

According to market data, Perrigo describes itself as the third-largest infant formula manufacturer in the US and Canada, having entered the category in the late nineties, and it owns US and Canadian rights to the Good Start brand from Nestle. MeridianMade operates factories in Pennsylvania, Iowa and Oregon, the publication reported, and its Chief Executive Officer Ron Belldegrun called the Acquisition a "commitment to responsible stewardship of store-brand infant formulas."

The transaction also arrives during a wider reshuffling of the formula industry. Abbott (NYSE:ABT) Laboratories has announced plans to spin off its infant formula and nutrition business into a standalone listed company, and Reckitt Benckiser remains in a long-running process to divest its baby food powders business and the Mead Johnson brand.

Manzone described the sale in the press release as an important step in making the group "a more focused consumer self-care company." Management also said it expects the transaction to improve margins, materially reduce future capital expenditures and support deleveraging. Bezerra said on the call that the divestiture removes a large amount of previously planned network capital spending, which may be the most consequential financial effect of the deal given the modest upfront cash.

Stabilize, Streamline, Strengthen

Manzone has organized his tenure, which he described on the call as his first months at the company, around a plan with stabilizing, streamlining and strengthening pillars. Under the streamlining pillar, the company has sold its Dermacosmetics business and agreed to the formula deal. A strategic review of Oral Care remains ongoing; Manzone said "the process is ongoing," and in response to a Canaccord Genuity analyst he indicated that oral care and one other asset are under review.

The Operational Enhancement Program delivered savings during the year to date and was described as remaining on track against its full-year goal. Under the strengthening pillar, Manzone said the company is "putting more Investment behind innovation, demand generation" in the areas of greatest opportunity. That includes positioning the digestive health portfolio to support consumers using the newer class of weight-management medications, with a product bundle rolling out across retailers.

Higher marketing already appears in the segment results, where it contributed to lower Self Care and Specialty Care profit in the quarter. The reinvestment therefore represents a near-term cost alongside the savings program, and the eventual return on that spending has yet to appear in the reported figures.

Balance Sheet Questions in Focus

Perrigo ended the quarter with total Debt far exceeding its cash balance, and net interest expense assumptions for the year moved slightly higher in the revised outlook. Net Leverage at year end is now expected at about the same multiple of adjusted EBITDA that the company previously described as a level it could match or slightly improve upon. The earlier wording of "at, or slightly lower than" has been dropped, a small but notable change.

Operating cash flow as a share of adjusted Net Income is also expected to come in somewhat lower than previously forecast. Net cash from Operating Activities was positive in the third quarter, and capital expenditures remained well below that amount. Over the year to date, however, Operating Cash Flow has been modest and the company has recorded a net loss that includes large impairment charges.

Dividends were a live topic. The company returned cash to shareholders through dividends in the quarter, and Manzone said management is "assessing the Dividend on a quarterly basis" while reviewing uses of capital across growth investments, debt reduction and Shareholder returns. Bezerra said proceeds from the formula divestiture would go toward growth, debt reduction and net leverage.

For readers who focus on cash generation and Balance Sheet capacity, those comments are as relevant as the earnings ranges. A company carrying leverage near the stated level, while evaluating the dividend each quarter and absorbing an impairment on an asset sale, has several competing claims on its cash, and management has not yet said how it will ultimately rank them beyond the priorities already listed.

What Comes Next on the Calendar

Several items now stand out as markers for the coming months. The first is how the cough and cold season develops, since management has tied any replenishment to that timing. The second is the fourth-quarter report, which will carry the first presentation of Infant Formula as discontinued operations and the expected impairment loss. The third is the outcome of the Oral Care review, along with any news on the other asset management mentioned on the call.

Closing of the MeridianMade transaction, expected in the first half of next year, is another milestone, as are the headwinds management has already flagged for next year from tax-rate normalization and the fading of tariff recoveries. A JPMorgan (NYSE:JPM) analyst raised next year's drivers on the call, and Bezerra sized the third-quarter tariff benefit as a small contributor in the context of the quarter's profit.

Perrigo describes itself as a leading provider of consumer self-care products and over-the-counter health and wellness solutions, focused on helping consumers prevent or treat self-manageable conditions. Whether the slimmer portfolio can return Core sales to growth remains the open question, one that the revised outlook suggests will not be settled this fiscal year.